Lisa Susan Wieland
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Lisa Susan Wieland has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Myeong Soo Lee
Korean Medicine Science Research Division, Korea Institute of Oriental Medicine, Daejeon, South Korea
15 shared publications - David Moher
Institute of Health Policy, Management & Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada
12 shared publications - Jeremy Yongwen Ng
Institute of General Practice and Interprofessional Care, University Hospital Tübingen, Tübingen, Germany
10 shared publications - Claudia Margitta Witt
Institute for Complementary and Integrative Medicine, University Hospital Zurich and University of Zurich, Zurich, Switzerland
8 shared publications - Holger Cramer
Institute of General Practice and Interprofessional Care, University Hospital Tübingen, Tübingen, Germany
7 shared publications Brian M Berman
Center for Integrative Medicine; University of Maryland School of Medicine; Baltimore Maryland USA
6 shared publications
Latest Publications
- Open Access
- 31 October 2026
- Published by Wiley in Cochrane Evidence Synthesis and Methods
- Vol. 4 (6) , e70110
Evaluating Certainty of Evidence Assessment in Systematic Reviews of Yoga for Health: A Meta‐Research Study
Background: The assessment of the trustworthiness and relevance of available evidence is a key element of evidence synthesis. For example, Cochrane systematic reviews (SRs) mandate the assessment of certainty of evidence (CoE) using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) method. However, most SRs are published outside Cochrane, and the use of CoE outside Cochrane is not universal. The use of CoE in SRs of yoga for maintaining or improving health is not known. Objective: To: (a) estimate the proportion of SRs of yoga for health that assessed CoE; (b) identify which CoE systems and domains were used; and (c) examine whether CoE assessment was associated with SR publication and methodological characteristics. Methods: The Cochrane Database of Systematic Reviews (CDSR), MEDLINE (Ovid), PubMed, EMBASE (Ovid), AMED (Ovid), CINAHL (EBSCO), and PsycINFO (EBSCO) were searched to April 25th 2024 for SRs of randomized controlled trials (RCTs) of yoga for health. Two reviewers independently screened studies against predefined eligibility criteria for SRs of yoga: the study (1) sought to comprehensively identify relevant RCTs on a yoga‐focused research question, (2) stated inclusion criteria for the studies, (3) searched at least one electronic database, and (4) reported the critical appraisal of the included studies. Data on SR characteristics and CoE were independently extracted from included SRs by two authors. Data analysis included frequencies and univariate and multivariable logistic regressions, conducted using R version 4.5.2. Statistical significance was set at p < .05. Results: A total of 250 SRs published between 2005 and 2025 were included. More than a third of the SRs (88/250; 35.2%) were published by authors based in Asia, America and Europe. Among the 246 reviews with included RCTs, 39 (16%, 95% CI = 11.8%–20.9%) assessed CoE for at least one effect estimate. Among reviews that assessed CoE, GRADE was the most frequently used framework (35/39, 89.7%). In multivariable analysis, CoE assessment was independently associated with presence of a meta‐analysis (OR = 3.01, 95% CI = 1.08–10.21), systematic‐review journal type (OR = 56.47, 95% CI = 5.33–1151.95), and use of a Cochrane risk‐of‐bias tool (OR = 12.17, 95% CI = 2.71–124.93). Region, journal impact factor, and study types included were not independently associated with CoE assessment after adjustment. Conclusion: Approximately 16% of SRs of yoga for health assessed CoE. Since this study was limited to English‐language studies identified from major databases through 2024, we cannot be certain whether this result reflects true levels of CoE assessment across all SRs of yoga for health conducted to date. Strengthening reviewer training, instituting journal requirements, and encouraging adherence to PRISMA and GRADE guidelines might increase the future percentage of yoga SRs assessing CoE.
- 31 October 2026
- Published by Wiley in Cochrane Evidence Synthesis and Methods
- Vol. 4 (6) , e70110
Open AccessEvaluating Certainty of Evidence Assessment in Systematic Reviews of Yoga for Health: A Meta‐Research Study
Background: The assessment of the trustworthiness and relevance of available evidence is a key element of evidence synthesis. For example, Cochrane systematic reviews (SRs) mandate the assessment of certainty of evidence (CoE) using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) method. However, most SRs are published outside Cochrane, and the use of CoE outside Cochrane is not universal. The use of CoE in SRs of yoga for maintaining or improving health is not known. Objective: To: (a) estimate the proportion of SRs of yoga for health that assessed CoE; (b) identify which CoE systems and domains were used; and (c) examine whether CoE assessment was associated with SR publication and methodological characteristics. Methods: The Cochrane Database of Systematic Reviews (CDSR), MEDLINE (Ovid), PubMed, EMBASE (Ovid), AMED (Ovid), CINAHL (EBSCO), and PsycINFO (EBSCO) were searched to April 25th 2024 for SRs of randomized controlled trials (RCTs) of yoga for health. Two reviewers independently screened studies against predefined eligibility criteria for SRs of yoga: the study (1) sought to comprehensively identify relevant RCTs on a yoga‐focused research question, (2) stated inclusion criteria for the studies, (3) searched at least one electronic database, and (4) reported the critical appraisal of the included studies. Data on SR characteristics and CoE were independently extracted from included SRs by two authors. Data analysis included frequencies and univariate and multivariable logistic regressions, conducted using R version 4.5.2. Statistical significance was set at p < .05. Results: A total of 250 SRs published between 2005 and 2025 were included. More than a third of the SRs (88/250; 35.2%) were published by authors based in Asia, America and Europe. Among the 246 reviews with included RCTs, 39 (16%, 95% CI = 11.8%–20.9%) assessed CoE for at least one effect estimate. Among reviews that assessed CoE, GRADE was the most frequently used framework (35/39, 89.7%). In multivariable analysis, CoE assessment was independently associated with presence of a meta‐analysis (OR = 3.01, 95% CI = 1.08–10.21), systematic‐review journal type (OR = 56.47, 95% CI = 5.33–1151.95), and use of a Cochrane risk‐of‐bias tool (OR = 12.17, 95% CI = 2.71–124.93). Region, journal impact factor, and study types included were not independently associated with CoE assessment after adjustment. Conclusion: Approximately 16% of SRs of yoga for health assessed CoE. Since this study was limited to English‐language studies identified from major databases through 2024, we cannot be certain whether this result reflects true levels of CoE assessment across all SRs of yoga for health conducted to date. Strengthening reviewer training, instituting journal requirements, and encouraging adherence to PRISMA and GRADE guidelines might increase the future percentage of yoga SRs assessing CoE.
- Open Access
- 9 October 2026
- Published by Elsevier in SSRN Electronic Journal
Making Reporting Guidelines Work: A Hybrid Checklist Approach to Improve Publication Quality and Success
Background: Reporting guidelines are central to improving transparency and quality in research. The EQUATOR Network was established over 15 years ago and catalogues more than 700 guidelines to date. Core guidelines such as CONSORT for clinical trials and PRISMA for systematic reviews, are supplemented by numerous extensions for different study designs, data types, interventions and other aspects of reporting. Despite this proliferation, inadequate reporting persists. Purpose: This article examines why reporting problems remain and provides practical strategies and tools to help authors navigate multiple, overlapping checklists more efficiently. Using traditional, complementary and integrative medicine (TCIM) as an example, 150 potentially relevant reporting checklists for primary clinical studies are listed to help researchers identify relevant reporting checklists and combine them into a single, consolidated hybrid checklist. Examples of hybrid reporting templates for different study designs and interventions are presented for authors to download and use. Discussion: Although many journals mandate adherence to standard reporting checklists, a key challenge facing authors is when several reporting checklists simultaneously apply to a study report because each covers specific aspects of the study design, methods, or interventions. This can be overwhelming, and result in omissions or duplications of reporting items and low compliance. For example, abstract reporting extensions are commonly overlooked, even though abstracts are the most accessed component of a study report and their quality may be a decisive factor in editorial and reviewer assessments. A hybrid checklist approach is therefore proposed where relevant reporting checklists are combined into a single checklist. Authors are encouraged to engage with reporting guidelines early in the research process to ensure key data are collected and documented and, therefore, can be reported. Conclusion: The proliferation of reporting guidelines has created both challenge and opportunity. Rather than viewing reporting checklists as mandatory journal submission paperwork, when used proactively reporting guidelines can play a valuable role in research planning and guide the writing process. When reporting checklists are consolidated into study-specific hybrid checklists, applied prospectively and updated as new guidance emerges, authors can transform the plethora of reporting guidelines into powerful tools to improve clarity, credibility and publication success.
- 9 October 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessMaking Reporting Guidelines Work: A Hybrid Checklist Approach to Improve Publication Quality and Success
Background: Reporting guidelines are central to improving transparency and quality in research. The EQUATOR Network was established over 15 years ago and catalogues more than 700 guidelines to date. Core guidelines such as CONSORT for clinical trials and PRISMA for systematic reviews, are supplemented by numerous extensions for different study designs, data types, interventions and other aspects of reporting. Despite this proliferation, inadequate reporting persists. Purpose: This article examines why reporting problems remain and provides practical strategies and tools to help authors navigate multiple, overlapping checklists more efficiently. Using traditional, complementary and integrative medicine (TCIM) as an example, 150 potentially relevant reporting checklists for primary clinical studies are listed to help researchers identify relevant reporting checklists and combine them into a single, consolidated hybrid checklist. Examples of hybrid reporting templates for different study designs and interventions are presented for authors to download and use. Discussion: Although many journals mandate adherence to standard reporting checklists, a key challenge facing authors is when several reporting checklists simultaneously apply to a study report because each covers specific aspects of the study design, methods, or interventions. This can be overwhelming, and result in omissions or duplications of reporting items and low compliance. For example, abstract reporting extensions are commonly overlooked, even though abstracts are the most accessed component of a study report and their quality may be a decisive factor in editorial and reviewer assessments. A hybrid checklist approach is therefore proposed where relevant reporting checklists are combined into a single checklist. Authors are encouraged to engage with reporting guidelines early in the research process to ensure key data are collected and documented and, therefore, can be reported. Conclusion: The proliferation of reporting guidelines has created both challenge and opportunity. Rather than viewing reporting checklists as mandatory journal submission paperwork, when used proactively reporting guidelines can play a valuable role in research planning and guide the writing process. When reporting checklists are consolidated into study-specific hybrid checklists, applied prospectively and updated as new guidance emerges, authors can transform the plethora of reporting guidelines into powerful tools to improve clarity, credibility and publication success.
- Open Access
- 31 August 2026
- Published by Wiley in Cochrane Evidence Synthesis and Methods
- Vol. 4 (5)
Development and Validation of PubMed and Ovid MEDLINE Search Filters for Exposure Pathways Linking Climate Change With Public Health
Introduction: Climate change has major health impacts to which researchers and policymakers need to respond. The volume and multidisciplinary nature of climate‐health evidence pose challenges to its comprehensive identification. Search filters are currently not available for this topic. Our aim was to empirically develop sensitivity‐maximizing climate‐health search filters for two interfaces of the MEDLINE database. Methods: Climate change impacts health via several exposure pathways involving distinct mechanisms: extreme weather events, heat stress, air quality, water quality and quantity, food supply and safety, vector distribution and ecology, and social factors. Using the relative recall method, we established a gold standard by extracting included studies of 110 evidence syntheses and classifying them into exposure pathways. From this set, we empirically derived and validated filters per pathway. Results: Based on 1572 primary studies indexed in PubMed, we developed filters with a sensitivity of 95%, 97% and 99% for six of the seven major climate‐health exposure pathways. Conclusion: We designed the first empirically derived search filters for climate‐health pathways, enabling sensitive retrieval despite acknowledged limitations. Our filters can be applied to different types of research questions at the intersection of climate and health.
- 31 August 2026
- Published by Wiley in Cochrane Evidence Synthesis and Methods
- Vol. 4 (5)
Open AccessDevelopment and Validation of PubMed and Ovid MEDLINE Search Filters for Exposure Pathways Linking Climate Change With Public Health
Introduction: Climate change has major health impacts to which researchers and policymakers need to respond. The volume and multidisciplinary nature of climate‐health evidence pose challenges to its comprehensive identification. Search filters are currently not available for this topic. Our aim was to empirically develop sensitivity‐maximizing climate‐health search filters for two interfaces of the MEDLINE database. Methods: Climate change impacts health via several exposure pathways involving distinct mechanisms: extreme weather events, heat stress, air quality, water quality and quantity, food supply and safety, vector distribution and ecology, and social factors. Using the relative recall method, we established a gold standard by extracting included studies of 110 evidence syntheses and classifying them into exposure pathways. From this set, we empirically derived and validated filters per pathway. Results: Based on 1572 primary studies indexed in PubMed, we developed filters with a sensitivity of 95%, 97% and 99% for six of the seven major climate‐health exposure pathways. Conclusion: We designed the first empirically derived search filters for climate‐health pathways, enabling sensitive retrieval despite acknowledged limitations. Our filters can be applied to different types of research questions at the intersection of climate and health.
- 27 August 2026
- Published by Elsevier in Phytomedicine
- Vol. 161, 158764
Traditional, complementary, and integrative medicine therapies for mild/moderate acute COVID-19: a systematic review and network meta-analysis
- 27 August 2026
- Published by Elsevier in Phytomedicine
- Vol. 161, 158764
Traditional, complementary, and integrative medicine therapies for mild/moderate acute COVID-19: a systematic review and network meta-analysis
- Open Access
Perceptions of Open Science in the Editorial and Peer Review Process: A Cross-Sectional Survey of Traditional, Complementary, and Integrative Medicine Journal Editors
Background: Open science (OS) offers opportunities to address challenges in the editorial and peer review processes of traditional, complementary, and integrative medicine (TCIM) journals. This study assessed TCIM journal editors’ perceptions of OS and the perceived benefits and challenges of integrating OS into editorial and peer review processes. Methods: A cross-sectional survey was distributed to editors-in-chief, associate editors, and editorial board members of 115 TCIM journals. The survey examined demographics, current use and familiarity with OS, perceived advantages and obstacles, and future perspectives on OS in academic publishing. Quantitative data were analyzed descriptively, and qualitative data were examined using thematic analysis. Results: A total of 267 respondents completed the survey, with most identifying as faculty members or academic research staff (n = 201/335, 60.0%). Most respondents were familiar (n = 128/212, 60.3%) or very familiar (n = 64/212, 30.2%) with OS practices, although many had received no formal OS training (n = 94/210, 44.8%). Respondents were most familiar with open access (n = 131/213, 61.5%) and preprints (n = 92/211, 43.6%). Among the seven OS practices examined, open access was viewed most favorably, with many considering it "very important" (n = 97/206, 47.1%) and strongly agreeing that it enhances the accessibility of research findings (n = 118/195, 60.5%). Conclusion: Most respondents were familiar with OS but held varying perceptions regarding the importance, advantages, and disadvantages of different OS practices. These findings may inform the development and implementation of evidence-based practices and policies that meet the needs of the TCIM research community.
Open AccessPerceptions of Open Science in the Editorial and Peer Review Process: A Cross-Sectional Survey of Traditional, Complementary, and Integrative Medicine Journal Editors
Background: Open science (OS) offers opportunities to address challenges in the editorial and peer review processes of traditional, complementary, and integrative medicine (TCIM) journals. This study assessed TCIM journal editors’ perceptions of OS and the perceived benefits and challenges of integrating OS into editorial and peer review processes. Methods: A cross-sectional survey was distributed to editors-in-chief, associate editors, and editorial board members of 115 TCIM journals. The survey examined demographics, current use and familiarity with OS, perceived advantages and obstacles, and future perspectives on OS in academic publishing. Quantitative data were analyzed descriptively, and qualitative data were examined using thematic analysis. Results: A total of 267 respondents completed the survey, with most identifying as faculty members or academic research staff (n = 201/335, 60.0%). Most respondents were familiar (n = 128/212, 60.3%) or very familiar (n = 64/212, 30.2%) with OS practices, although many had received no formal OS training (n = 94/210, 44.8%). Respondents were most familiar with open access (n = 131/213, 61.5%) and preprints (n = 92/211, 43.6%). Among the seven OS practices examined, open access was viewed most favorably, with many considering it "very important" (n = 97/206, 47.1%) and strongly agreeing that it enhances the accessibility of research findings (n = 118/195, 60.5%). Conclusion: Most respondents were familiar with OS but held varying perceptions regarding the importance, advantages, and disadvantages of different OS practices. These findings may inform the development and implementation of evidence-based practices and policies that meet the needs of the TCIM research community.
- Open Access
- 14 May 2026
- Published by Elsevier in Integrative Medicine Research
- Vol. 15 (4) , 101352
Sham acupuncture techniques are not inert: An overview
- 14 May 2026
- Published by Elsevier in Integrative Medicine Research
- Vol. 15 (4) , 101352
Open AccessSham acupuncture techniques are not inert: An overview
- 30 March 2026
- Published by SAGE Publications in Journal of Integrative and Complementary Medicine
- Vol. 32 (5) , 404-406
Synopses of Cochrane Reviews from Cochrane Library Issue 10 2025 Through Issue 1 2026
- 30 March 2026
- Published by SAGE Publications in Journal of Integrative and Complementary Medicine
- Vol. 32 (5) , 404-406
Synopses of Cochrane Reviews from Cochrane Library Issue 10 2025 Through Issue 1 2026
- 5 February 2026
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2026 (2) , CD013661
Ginkgo biloba for cognitive impairment and dementia
Background Dementia is a neurocognitive disorder that interferes with cognition and independent functioning. Common dementia subtypes include Alzheimer's disease, vascular dementia, and mixed type. Mild cognitive impairment (MCI) is a risk factor for dementia, and subjective cognitive complaints may be the earliest manifestation. Although cholinesterase inhibitors may help reduce some cognitive and behavioral symptoms, there is no established treatment that cures or slows dementia progression. Ginkgo biloba (ginkgo) is a popular herbal preparation that is used to improve brain and circulatory health, and neuroprotective effects are biologically plausible. Objectives To assess the benefits and harms of Ginkgo biloba for the treatment of people with cognitive impairment or dementia. Search methods We searched the Cochrane Dementia and Cognitive Improvement Group's register, MEDLINE, Embase, four other databases, and two trials registries on 8 December 2022. The search was updated in MEDLINE, Embase, CENTRAL, and the trials registers on 18 November 2024. Selection criteria We included randomized controlled trials (RCTs) comparing ginkgo with placebo, usual treatment, or other treatments for cognitive problems in people with cognitive complaints or diagnoses of MCI or dementia. Data collection and analysis Two review authors independently selected trials, extracted data, and assessed studies for risk of bias. Key outcomes were global clinical status, global cognitive function, activities of daily living (ADLs), adverse events (AEs), and serious adverse events (SAEs) at six months. When clinically appropriate, we pooled data using a random‐effects model and expressed treatment effects as mean differences (MDs), standardized mean differences (SMDs), or risk ratios (RRs), each with its 95% confidence interval (CI). We used GRADE methods to assess the certainty of the evidence for each estimate. Main results We included 82 studies with 10,613 participants; 72 studies with 9783 participants provided extractable data. Four studies were at low risk of bias in all domains. Below we present data for the comparison of ginkgo versus placebo in people with different clinical conditions. Subjective cognitive impairment Three studies (597 participants) compared ginkgo with placebo for people with subjective cognitive complaints. Based on one study that lasted six months, it is uncertain whether ginkgo has any effect on global clinical status measured on a five‐point Likert scale (MD 0.00, 95% CI −0.33 to 0.33; P = 1.00; 1 study, 197 participants; very low‐certainty evidence). There were no data on cognition or ADLs. One study reported no difference in minor side effects between treatment groups and did not mention SAEs. A larger study lasting three months found that the risk of AEs may be higher with ginkgo versus placebo. It provided very uncertain evidence on the risk of SAEs. Multiple sclerosis and cognitive impairment Two studies (164 participants) tested ginkgo versus placebo over three months in people with multiple sclerosis and cognitive problems. Ginkgo probably has little or no effect on cognition measured on the Perceived Deficits Questionnaire (MD −0.09, 95% CI −0.41 to 0.22; P = 0.55, I² = 0%; 2 studies, 152 participants; moderate‐certainty evidence). There were no data on global clinical status or ADLs. The studies suggested no important difference in numbers of AEs between groups, and there was no indication of SAEs due to ginkgo. Mild cognitive impairment Twelve studies (1913 participants) tested ginkgo against placebo in people with MCI. At six months, moderate‐certainty evidence suggests that ginkgo probably has little to no effect on global clinical status measured on the Clinical Dementia Rating Scale (MD −0.03, 95% CI −0.06 to 0.01; 3 studies, 631 participants; I² = 0%), cognition measured on the Alzheimer's Disease Assessment Scale – cognition (MD −0.07, 95% CI −0.67 to 0.51; I² = 0%; 2 studies, 508 participants), and ADLs measured on the Instrumental ADL scale (MD −0.05, 95% CI −0.29 to 0.19; 1 study, 350 participants). There may be little or no difference between ginkgo and placebo at up to 12 months in the risk of AEs (RR 0.98, 95% CI 0.77 to 1.24; I² = 58%; 7 studies, 991 participants, 379 events; low‐certainty evidence), and there is little or no difference in the risk of SAEs (RR 0.95, 95% CI 0.82 to 1.09; I² = 0%; 3 studies, 714 participants, 327 events; high‐certainty evidence). Dementia Thirteen studies (3288 participants) compared ginkgo with placebo for dementia. At six months, low‐certainty evidence suggests that people taking ginkgo may have better global clinical status on a six‐point Likert scale (lower is better; MD −0.06, 95% CI −1.00 to −0.20; I² = 88%; 5 studies, 1359 participants), better cognition measured by decreases on a short cognitive performance test (Syndrom‐Kurztest; MD −1.86, 95% CI −3.48 to −0.24; I² = 96%; 9 studies, 2801 participants), and slightly better ADLs measured on the ADL International Scale (MD −0.19, 95% CI −0.35 to −0.03; I² = 91%; 8 studies, 2571 participants). There is probably little or no difference between ginkgo and placebo in the risk of AEs at up to 12 months (RR 0.95, 95% CI 0.90 to 1.00; I² = 0%; 9 studies, 2746 participants, 1480 events; moderate‐certainty evidence). There may be little or no difference in risk of SAEs at six months (RR 0.88, 95% CI 0.58 to 1.33; I² = 0%; 6 studies, 2463 participants, 89 events; low‐certainty evidence). Authors' conclusions In people with cognitive complaints, we are unsure whether ginkgo improves global clinical status at six months, and it may be associated with an increased risk of AEs at three months. Ginkgo probably has no benefit at three months for cognition in multiple sclerosis; numeric data on AEs were unavailable, but studies did not suggest concerns. In people with MCI, ginkgo probably has little or no effect at six months on global status, cognition, or ADLS. There may be little or no difference in AEs, and there is little or no difference in SAEs, at up to 12 months. In people with dementia, there may be small to moderate benefits at six months for global status, cognition, and ADLs. There is probably little or no difference in AEs at up to 12 months, and there may be no difference in SAEs.
- 5 February 2026
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2026 (2) , CD013661
Ginkgo biloba for cognitive impairment and dementia
Background Dementia is a neurocognitive disorder that interferes with cognition and independent functioning. Common dementia subtypes include Alzheimer's disease, vascular dementia, and mixed type. Mild cognitive impairment (MCI) is a risk factor for dementia, and subjective cognitive complaints may be the earliest manifestation. Although cholinesterase inhibitors may help reduce some cognitive and behavioral symptoms, there is no established treatment that cures or slows dementia progression. Ginkgo biloba (ginkgo) is a popular herbal preparation that is used to improve brain and circulatory health, and neuroprotective effects are biologically plausible. Objectives To assess the benefits and harms of Ginkgo biloba for the treatment of people with cognitive impairment or dementia. Search methods We searched the Cochrane Dementia and Cognitive Improvement Group's register, MEDLINE, Embase, four other databases, and two trials registries on 8 December 2022. The search was updated in MEDLINE, Embase, CENTRAL, and the trials registers on 18 November 2024. Selection criteria We included randomized controlled trials (RCTs) comparing ginkgo with placebo, usual treatment, or other treatments for cognitive problems in people with cognitive complaints or diagnoses of MCI or dementia. Data collection and analysis Two review authors independently selected trials, extracted data, and assessed studies for risk of bias. Key outcomes were global clinical status, global cognitive function, activities of daily living (ADLs), adverse events (AEs), and serious adverse events (SAEs) at six months. When clinically appropriate, we pooled data using a random‐effects model and expressed treatment effects as mean differences (MDs), standardized mean differences (SMDs), or risk ratios (RRs), each with its 95% confidence interval (CI). We used GRADE methods to assess the certainty of the evidence for each estimate. Main results We included 82 studies with 10,613 participants; 72 studies with 9783 participants provided extractable data. Four studies were at low risk of bias in all domains. Below we present data for the comparison of ginkgo versus placebo in people with different clinical conditions. Subjective cognitive impairment Three studies (597 participants) compared ginkgo with placebo for people with subjective cognitive complaints. Based on one study that lasted six months, it is uncertain whether ginkgo has any effect on global clinical status measured on a five‐point Likert scale (MD 0.00, 95% CI −0.33 to 0.33; P = 1.00; 1 study, 197 participants; very low‐certainty evidence). There were no data on cognition or ADLs. One study reported no difference in minor side effects between treatment groups and did not mention SAEs. A larger study lasting three months found that the risk of AEs may be higher with ginkgo versus placebo. It provided very uncertain evidence on the risk of SAEs. Multiple sclerosis and cognitive impairment Two studies (164 participants) tested ginkgo versus placebo over three months in people with multiple sclerosis and cognitive problems. Ginkgo probably has little or no effect on cognition measured on the Perceived Deficits Questionnaire (MD −0.09, 95% CI −0.41 to 0.22; P = 0.55, I² = 0%; 2 studies, 152 participants; moderate‐certainty evidence). There were no data on global clinical status or ADLs. The studies suggested no important difference in numbers of AEs between groups, and there was no indication of SAEs due to ginkgo. Mild cognitive impairment Twelve studies (1913 participants) tested ginkgo against placebo in people with MCI. At six months, moderate‐certainty evidence suggests that ginkgo probably has little to no effect on global clinical status measured on the Clinical Dementia Rating Scale (MD −0.03, 95% CI −0.06 to 0.01; 3 studies, 631 participants; I² = 0%), cognition measured on the Alzheimer's Disease Assessment Scale – cognition (MD −0.07, 95% CI −0.67 to 0.51; I² = 0%; 2 studies, 508 participants), and ADLs measured on the Instrumental ADL scale (MD −0.05, 95% CI −0.29 to 0.19; 1 study, 350 participants). There may be little or no difference between ginkgo and placebo at up to 12 months in the risk of AEs (RR 0.98, 95% CI 0.77 to 1.24; I² = 58%; 7 studies, 991 participants, 379 events; low‐certainty evidence), and there is little or no difference in the risk of SAEs (RR 0.95, 95% CI 0.82 to 1.09; I² = 0%; 3 studies, 714 participants, 327 events; high‐certainty evidence). Dementia Thirteen studies (3288 participants) compared ginkgo with placebo for dementia. At six months, low‐certainty evidence suggests that people taking ginkgo may have better global clinical status on a six‐point Likert scale (lower is better; MD −0.06, 95% CI −1.00 to −0.20; I² = 88%; 5 studies, 1359 participants), better cognition measured by decreases on a short cognitive performance test (Syndrom‐Kurztest; MD −1.86, 95% CI −3.48 to −0.24; I² = 96%; 9 studies, 2801 participants), and slightly better ADLs measured on the ADL International Scale (MD −0.19, 95% CI −0.35 to −0.03; I² = 91%; 8 studies, 2571 participants). There is probably little or no difference between ginkgo and placebo in the risk of AEs at up to 12 months (RR 0.95, 95% CI 0.90 to 1.00; I² = 0%; 9 studies, 2746 participants, 1480 events; moderate‐certainty evidence). There may be little or no difference in risk of SAEs at six months (RR 0.88, 95% CI 0.58 to 1.33; I² = 0%; 6 studies, 2463 participants, 89 events; low‐certainty evidence). Authors' conclusions In people with cognitive complaints, we are unsure whether ginkgo improves global clinical status at six months, and it may be associated with an increased risk of AEs at three months. Ginkgo probably has no benefit at three months for cognition in multiple sclerosis; numeric data on AEs were unavailable, but studies did not suggest concerns. In people with MCI, ginkgo probably has little or no effect at six months on global status, cognition, or ADLS. There may be little or no difference in AEs, and there is little or no difference in SAEs, at up to 12 months. In people with dementia, there may be small to moderate benefits at six months for global status, cognition, and ADLs. There is probably little or no difference in AEs at up to 12 months, and there may be no difference in SAEs.